Primary and secondary coenzyme Q10 deficiency: The role of therapeutic supplementation

Nutrition Reviews

Volumn 71, Issue 3, 2013, Pages 180-188

  Potgieter, Marnie ^a   Pretorius, Etheresia ^a   Pepper, Michael S ^a  

^a University of Pretoria   (South Africa)

Author keywords

Antioxidant; CoQ10; CoQ10 deficiency; Hypercholesterolemia; Statins; Supplementation

Indexed keywords

CERIVASTATIN; CREATINE KINASE; CYCLIC GMP; ELECTRON TRANSFERRING FLAVOPROTEIN; ELECTRON TRANSFERRING FLAVOPROTEIN DEHYDROGENASE; GLUTAMATE RECEPTOR 5; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LACTIC ACID; MEVALONIC ACID; UBIDECARENONE; UNCLASSIFIED DRUG; WARFARIN;

BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY METABOLISM; ENZYME DEFICIENCY; ENZYME METABOLISM; ENZYME SYNTHESIS; ENZYME THERAPY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LACTATE BLOOD LEVEL; NAUSEA; NONHUMAN; OXIDATION REDUCTION STATE; PRIMARY COENZYME Q10 DEFICIENCY; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SECONDARY COENZYME Q10 DEFICIENCY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUTATION; UBIQUINONE;

EID: 84874471154     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/nure.12011     Document Type: Review

References (72)

1. Linnane AW, Kopsidas G, Zhang C, etal. Cellular redox activity of coenzyme Q10: effect of CoQ10 supplementation on human skeletal muscle. Free Radic Res. 2002;36:445-453.
2. Collins C, Kemper KJ, The Longwood Herbal Task Force. Coenzyme Q10 (CoQ10 or Ubiquinone). 1999; Available at: http://www.longwoodherbal.org/coq10/coq10.PDF. Accessed 9 January 2013.
3. Ernster L. Facts and ideas about the function of coenzyme Q10 in the mirochondria. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier; 1977:15-18.
4. Quinzii CM, DiMauro S, Hirano M. Human coenzyme Q10 deficiency. Neurochem Res. 2007;32:723-727.
5. Sohal R, Forster MJ. Coenzyme Q, oxidative stress and aging. Mitochondrion. 2007;7(Suppl):S103-S111.
6. Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med. 2000;29:285-294.
7. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195-204.
8. Bhakgavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006;40:445-453.
9. Tran UC, Clarke FC. Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion. 2007;7(Suppl):S62-S71.
10. Folkers K. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer therapy. Biochem Biophys Res Commun. 1996;224:358-361.
11. Turunen M, Olsen J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660:171-199.
12. Fernández-Ayala DJM, López-Lluch G, García-Valdés M, etal. Specificity of coenzyme Q10 for a balanced function of respiratory chain and endogenous ubiquinone biosynthesis in human cells. Biochim Biophys Acta. 2005;1706:174-183.
13. Clarke CF. New advances in coenzyme Q biosynthesis. Protoplasma. 2000;213:134-147.
14. Folkers K. The potential of coenzyme Q10 (NSC-140865) in cancer treatment. Cancer Chemother Rep. 1974;24:19-23.
15. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to coenzyme Q10 and contribution to normal energy-yielding metabolism, maintenance of normal blood pressure, protection of DNA, proteins and lipids from oxidative damage, contribution to normal cognitive function, maintenance of normal blood cholesterol concentrations and increase in endurance capacity and/or endurance performance pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2010;8:1793.
16. Ogasahara S, Engel AG, Frens D, etal. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-2382.
17. Quinzii CM, Hirano M, DiMauro S. CoQ10 deficiency diseases in adults. Mitochondrion. 2007;7(Suppl):S122-S126.
18. López LC, Schuelke M, Quinzii CM, etal. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006;79:1125-1129.
19. Quinzii C, Naini A, Salviati L, etal. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006;78:345-349.
20. Mollet J, Giurgea I, Schlemmer D, etal. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007;117:765-772.
21. Mollet J, Delahodde A, Serre V, etal. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet. 2008;82:623-630.
22. Duncan AJ, Bitner-Glindzics M, Meunier B, etal. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84:558-566.
23. Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008;358:2849-2850.
24. Quinzii CM, López LC, Naini A, etal. Human CoQ10 deficiencies. Biofactors. 2008;32:113-118.
25. Quinzii CM, Kattah AG, Naini A, etal. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology. 2005;64:539-541.
26. Date H, Onodera O, Tanaka H, etal. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new hit superfamily gene. Nat Genet. 2001;29:184-188.
27. Moreira MC, Barbot C, Tachi N, etal. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet. 2001;29:189-193.
28. DiMauro S, Quinzii CM, Hirano M. Mutations in coenzyme Q10 biosynthetic genes. J Clin Invest. 2007;117:587-589.
29. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16:183-188.
30. Gempel K, Topaloglu H, Talim B, etal. The myopathic form of coenzyme Q10 deficiency is caused by mutation in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130:2037-2044.
31. Hübner C, Hoffman GF, Charpentier C, etal. Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr Res. 1993;34:129-133.
32. 10 in rats. Chem Pharm Bull. 1972;250:2585-2592.
33. Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (ubiquinone). Regul Toxicol Pharmacol. 2006;45:282-288.
34. Ferrante KL, Shefner J, Zhang H, etal. Tolerance of high-dose (3, 000mg/day) coenzyme Q10 in ALS. Neurology. 2005;65:1834-1836.
35. Musumeci O, Naini A, Slonim AE, etal. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology. 2001;56:849-855.
36. Shults CW, Flint Beal M, Song D, etal. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004;188:491-494.
37. Landbo C, Almdal TP. Interaction between warfarin and coenzyme Q10. Ugeskr Laeger. 1998;160:3226-3227.
38. Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger. 2003;165:1868-1871.
39. Molyneux S, Florkowski C, McGrane Y, etal. Concentration response to the coenzyme Q10 supplement Q-Gel in human volunteers. Nutr Res. 2007;27:307-312.
40. Weber C, Bysted A, Holmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res. 1997;67:123-129.
41. Berthold HK, Naini A, Di Mauro S, etal. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomized trial. Drug Saf. 2006;29:703-712.
42. Bank G, Kagan D, Madhavi D. Coenzyme Q10: clinical update and bioavailability. Evid Based Complement Alternat. 2011;16:129-137.
43. Singh RB, Niaz MA, Kumar A, etal. Effect on absorption and oxidative stress of different oral coenzyme Q10 dosages and intake strategy in healthy men. Biofactors. 2006;25:219-224.
44. Lu J, Frank EL. Measurement of coenzyme Q10 in clinical practice. Clin Chim Acta. 2007 384:180-181.
45. Linnane AW, Degli Esposti M, Generowicz M, etal. The universality of bioenergetic disease and amelioration with redox therapy. Biochim Biophys Acta. 1995;1271:191-194.
46. Al-Sulaiman AA, Al-Khamis AA. Statin-induced myopathy: a clinical perspective. 2009; Available at: http://www.bahrainmedicalbulletin.com/june_2009/Statin_Induced_Myopathy.pdf. Accessed 28 December 2012.
47. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7(Suppl):S168-S174.
48. Baigent C, Keech A, Kearney PM, etal. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267-1278.
49. Vaklavas C, Chatzizisis YS, Ziakas A, etal. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202:18-28.
50. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
51. Sathasivam S, Lecky B. Statin induced myopathy. BMJ. 2008;337:1159-1162.
52. Pasternak RC, Smith SC Jr, Bairey-Merz CN, etal. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
53. Phillips PS, Hassa RH, Bannykh S. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
54. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol. 2007;49:2231-2237.
55. Wills RA, Folkers K, Tucker JL, etal. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A. 1990;87:8928-8930.
56. Folkers K, Langsjoen P, Willis R, etal. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87:8931-8934.
57. Miyake Y, Shouzu A, Nishikawa M, etal. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetes patients. Arzneimittelforschung. 1999;49:324-329.
58. Bleske BE, Willis RA, Anthony M, etal. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J. 2001;142:e2.
59. Molyneux SL, Florkowski CM, George PM, etal. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol. 2008;52:1435-1441.
60. Tsivgoulis G, Spengos K, Karandreas N, etal. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166:1519-1524.
61. Caso G, Kelly P, McNurlan MA, etal. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409-1412.
62. Young JM, Florowski CM, Molyneux SL, etal. Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400-1403.
63. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci. 2003;60:1118-1134.
64. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996;271:5289-5292.
65. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31:572-580.
66. Flint OP, Master BA, Gregg RE, etal. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145:99-110.
67. Nishimoto T, Ishikawa E, Anayama H, etal. Protective effects of squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223:39-45.
68. Liao JK. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011;123:1925-1928.
69. Stein EA, Bays H, O'Brien D, etal. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011;123:1974-1985.
70. Masters BA, Palmoski MJ, Flint OP, etal. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163-174.
71. Oh J, Ban MR, Miskie BA, etal. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7-12.
72. TM Q10). Int J Food Sci Nutr. 2006;57:546-555.